Rare Drivers in Metastatic Non-Small-Cell Lung Cancer with a Focus on EGFR Exon 20 Insertion Mutations

Expert thoracic oncologists discuss the importance of comprehensive molecular testing and optimal use of novel targeted agents in metastatic non-small cell lung cancer.

EP. 1: Lung Cancer: Molecular Testing

July 29th 2021

Alexander Spira, MD, PhD, FACP, shares an overview of the molecular testing needed for non–small cell lung cancer and his preferences for testing.

EP. 2: Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

July 29th 2021

Clinical trial data and implications for treating patients with metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations with mobocertinib.

EP. 3: Adverse Events Associated With Mobocertinib

July 29th 2021

Common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors, as well as management strategies are discussed.

EP. 4: New Therapies in Non–Small Cell Lung Cancer

August 5th 2021

Alexander Spira, MD, PhD, FACP, highlights emerging targeted agents to treat non–small cell lung cancer with actionable mutations.

EP. 5: Unmet Needs in Non–Small Cell Lung Cancer

August 5th 2021

Unmet needs including strategies to manage brain metastases in non–small cell lung cancer patients are presented.

EP. 6: Targeted Therapy for Metastatic Non–small Cell Lung Cancer

August 12th 2021

Mark A. Socinski, MD shares a brief overview of the biomarkers and FDA-approved targeted therapies for non–small cell lung cancers.

EP. 7: Non–small Cell Lung Cancer With EGFR Exon 20 Insertion

August 12th 2021

Rare drivers such as EGFR exon 20 insertions and what they mean for treatment of patients with metastatic non–small cell lung cancer.

EP. 8: EGFR Exon 20–Directed Therapy With Mobocertinib

August 12th 2021

Potential implications for treating patients with metastatic non–small cell lung cancers with EGFR exon 20 insertion mutations with mobocertinib, based on the EXCLAIM cohort.

EP. 9: EGFR Tyrosine Kinase Inhibitors and Brain Metastases

August 12th 2021

Commentary on the use of EGFR tyrosine kinase inhibitors and their efficacy on non–small cell lung cancer brain metastases.

EP. 10: Mobocertinib’s Safety Profile

August 19th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.